Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective

References

• Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019 Dec 17;10:2965. doi: 10.3389/fimmu.2019.02965
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Sep 23;363(13):711–723. doi: 10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8(Spec Feature):180–183.
   PubMedGoogle Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi: 10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi: 10.1056/NEJMoa1910836
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Maio M. Nivolumab plus ipilimumab in melanoma brain metastases. Lancet Oncol. 2022;23(2):e53. doi: 10.1016/S1470-2045(22)00001-8
   PubMedGoogle Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. doi: 10.1056/NEJMoa2109970
   PubMed Web of Science ®Google Scholar
• Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015;95(2):133–139. doi: 10.2340/00015555-1931
   PubMed Web of Science ®Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233. doi: 10.1136/annrheumdis-2017-212196
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. [published correction appears in Lancet. 2008 May 31;371(9627):1838]. doi: 10.1016/S0140-6736(08)60725-4
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Boehncke WH. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol. 2023 May 22;14:1186455. doi: 10.3389/fimmu.2023.1186455
   PubMed Web of Science ®Google Scholar
• Vu A, Ulschmid C, Gordon KB. Anti-IL 23 biologics for the treatment of plaque psoriasis [published correction appears in expert opin biol ther. Expert Opin Biol Ther. 2022 Dec 5;22(12):1489–1502. doi: 10.1080/14712598.2022.2132143
   PubMed Web of Science ®Google Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014.
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Moirano G, Fava P, et al. Obesity and immune-checkpoint inhibitors in advanced melanoma: a meta-analysis of survival outcomes from clinical studies, 2023 Mar 3. Semin Cancer Biol. 2023;91:S27–34. doi: 10.1016/j.semcancer.2023.02.010
   PubMed Web of Science ®Google Scholar
• Han J, Zhao Y, Shirai K, et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer. 2021;2(3):300–311. doi: 10.1038/s43018-021-00180-1
   PubMedGoogle Scholar
• Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807–3814. doi: 10.1200/JCO.2017.73.2289
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267. doi: 10.1038/s41571-022-00600-w
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Mastorino L, Susca S, et al. Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents. Clin Exp Dermatol. 2023 Nov 29;48(4):379–381. doi: 10.1093/ced/llac098
   PubMed Web of Science ®Google Scholar
• Topaloğlu Demir F, Polat Ekinci A, Aytekin S, et al. Clinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic. J Cosmet Dermatol. 2023;22(3):722–731. doi: 10.1111/jocd.15638
   PubMed Web of Science ®Google Scholar
• https://training.seer.cancer.gov/treatment/biotherapy/types
   Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi: 10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar
• Trojaniello C, Sparano F, Cioli E, et al. Sequencing targeted and immune therapy in BRAF-Mutant melanoma: lessons learned. Curr Oncol Rep. 2023;25(6):623–634. doi: 10.1007/s11912-023-01402-8
   PubMed Web of Science ®Google Scholar
• Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021 Apr 1;19(4):364–376. doi: 10.6004/jnccn.2021.0018
   PubMed Web of Science ®Google Scholar
• Perrone V, Losi S, Sabatino S, et al. Analysis of drug utilization in patients with psoriasis: a real-world retrospective study among the Italian population. Psoriasis (Auckl). 2023 Mar 2;13:1–9.
   PubMed Web of Science ®Google Scholar
• Mastorino L, Castelli F, Stroppiana E, et al. Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients. J Eur Acad Dermatol Venereol. 2022;36(10):e838–e841. doi: 10.1111/jdv.18314
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen Z, Gong Y, et al. A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis. Clin Drug Investig. 2018;38(3):191–199. doi: 10.1007/s40261-017-0603-3
   PubMed Web of Science ®Google Scholar
• Amaral T, Seeber O, Mersi E, et al. Primary resistance to PD-1-Based immunotherapy-A study in 319 patients with stage IV melanoma. Cancers (Basel). 2020 Apr 22;12(4):1027. doi: 10.3390/cancers12041027
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Cortese A, et al. Intra-class switch among IL-23 inhibitors for plaque psoriasis: is it worth it? Clin Drug Investig. 2023;43(5):365–367. doi: 10.1007/s40261-023-01271-w
   PubMed Web of Science ®Google Scholar
• Diotallevi F, Paolinelli M, Radi G, et al. Latest combination therapies in psoriasis: narrative review of the literature. Dermatol Ther. 2022;35(10):e15759. doi: 10.1111/dth.15759
   PubMed Web of Science ®Google Scholar
• Robert C, Carlino MS, McNeil C, et al. Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol. 2023;41(24):3998–4003. doi: 10.1200/JCO.22.01599
   PubMed Web of Science ®Google Scholar
• Chatziioannou E, Leiter U, Thomas I, et al. Features and long-term outcomes of stage IV melanoma patients achieving complete response under anti-PD-1-Based immunotherapy. Am J Clin Dermatol. 2023;24(3):453–467. doi: 10.1007/s40257-023-00775-7
   PubMed Web of Science ®Google Scholar
• Rubatto M, Fava P, Stanganelli I, et al. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian melanoma intergroup. Eur J Cancer. 2023;187:25–35. doi: 10.1016/j.ejca.2023.03.020
   PubMed Web of Science ®Google Scholar
• Tian D, Lai Y. The relapse of psoriasis: mechanisms and mysteries. JID Innov. 2022 Mar 9;2(3):100116. doi: 10.1016/j.xjidi.2022.100116
   PubMedGoogle Scholar
• Mehta H, Mashiko S, Angsana J, et al. Differential changes in inflammatory mononuclear phagocyte and T-Cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab. J Invest Dermatol. 2021;141(7):1707–1718.e9. doi: 10.1016/j.jid.2021.01.005
   PubMed Web of Science ®Google Scholar
• Whitley SK, Li M, Kashem SW, et al. Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells. Sci Immunol. 2022;7(77):eabq3254. doi: 10.1126/sciimmunol.abq3254
   PubMed Web of Science ®Google Scholar
• Michielsens CAJ, van Muijen ME, Verhoef LM, et al. Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs. 2021;81(3):349–366. doi: 10.1007/s40265-020-01448-z
   PubMed Web of Science ®Google Scholar
• Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019;5(9):1310–1317. doi: 10.1001/jamaoncol.2019.1022
   PubMed Web of Science ®Google Scholar
• Persigehl T, Lennartz S, Schwartz LH. iRECIST: how to do it. Cancer Imaging. 2020 Jan 3;20(1):2.
   PubMed Web of Science ®Google Scholar
• Svoboda SA, Ghamrawi RI, Owusu DA, et al. Treatment goals in psoriasis: which outcomes matter most? Am J Clin Dermatol. 2020;21(4):505–511. doi: 10.1007/s40257-020-00521-3
   PubMed Web of Science ®Google Scholar
• Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44(7):946–953. doi: 10.1016/j.ejca.2008.03.006
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi: 10.1056/NEJMc1713444
   PubMed Web of Science ®Google Scholar
• Turchin I, Bourcier M. The role of interleukins in the pathogenesis of dermatological immune-mediated diseases. Adv Ther. 2022;39(10):4474–4508. doi: 10.1007/s12325-022-02241-y
   PubMed Web of Science ®Google Scholar
• Mahdavi Gorabi A, Sadat Ravari M, Sanaei MJ, et al. Immune checkpoint blockade in melanoma: advantages, shortcomings and emerging roles of the nanoparticles. Int Immunopharmacol. 2022;113(Pt A):109300. doi: 10.1016/j.intimp.2022.109300
   PubMedGoogle Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345–361. doi: 10.1007/s40257-017-0336-3
   PubMed Web of Science ®Google Scholar
• Tartari F, Santoni M, Burattini L, et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20–24. doi: 10.1016/j.ctrv.2016.06.002
   PubMed Web of Science ®Google Scholar
• Bohensky MA, Pasupathi K, Gorelik A, et al. A cost-effectiveness analysis of Nivolumab compared with ipilimumab for the treatment of BRAF wild-type advanced melanoma in Australia. Value Health. 2016;19(8):1009–1015. doi: 10.1016/j.jval.2016.05.013
   PubMed Web of Science ®Google Scholar
• Chen BK, Yang YT, Bennett CL. Why biologics and biosimilars remain so expensive: despite two wins for biosimilars, the supreme court’s recent rulings do not solve fundamental barriers to competition. Drugs. 2018;78(17):1777–1781. doi: 10.1007/s40265-018-1009-0
   PubMed Web of Science ®Google Scholar
• Masson Regnault M, Shourick J, Jendoubi F, et al. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. Am J Clin Dermatol. 2022;23(4):433–447. doi: 10.1007/s40257-022-00679-y
   PubMed Web of Science ®Google Scholar
• Naldi L, Cazzaniga S, Di Mercurio M, et al. Psocare study centres. Inequalities in access to biological treatments for psoriasis: results from the Italian psocare registry. Br J Dermatol. 2017;176(5):1331–1338. doi: 10.1111/bjd.15234
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Micali G, et al. Management of advanced invasive melanoma: new strategies. Adv Ther. 2023;40(8):3381–3394. doi: 10.1007/s12325-023-02555-5
   PubMed Web of Science ®Google Scholar
• Adamczyk M, Bartosińska J, Raczkiewicz D, et al. The impact of biologic treatment on PD-1/PD-L1 pathway disturbances in psoriasis. J Clin Med. 2023 Jun 21;12(13):4179. doi: 10.3390/jcm12134179
   PubMed Web of Science ®Google Scholar
• Krzysztofik M, Brzewski P, Cuber P, et al. Risk of melanoma and non-melanoma skin cancer in patients with Psoriasis and psoriatic arthritis treated with targeted therapies: a systematic review and meta-analysis. Pharmaceuticals (Basel). 2023 Dec 21;17(1):14. doi: 10.3390/ph17010014
   PubMedGoogle Scholar
• Halle BR, Betof Warner A, Zaman FY, et al. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer. 2021;9(10):e003066. doi: 10.1136/jitc-2021-003066
   PubMed Web of Science ®Google Scholar